Life Technologies Launches New in vivo siRNA Gene-Silencing Kits and Reagents
by Mauricio Minotta - 10/25/10
CARLSBAD, Calif., Oct. 25, 2010 – Life Technologies Corporation, a provider of innovative life science solutions, today announced the introduction of Invivofectamine® 2.0 Reagent and Ambion® In Vivo siRNA – two new products that will enable researchers to perform efficient siRNA silencing (gene “knock-down”) experiments in small animal models.
Product tests by Life Technologies scientists produced effective targeted gene silencing lasting more than three weeks with a single application of Invivofectamine® 2.0 Reagent and the positive control Ambion® In Vivo siRNA. They also effectively knocked down up to four genes simultaneously with a single application of four different siRNA molecules. The new reagents provide a powerful alternative to the conventional use of knock-out mouse models, which can take nearly 10-months to develop.
Over the last decade, life science researchers have used siRNA (small interfering RNA) to elucidate the function of many genes, a key step in validating potential targets in the drug discovery process. However, the lack of robust tools on the market for in vivo experiments has been a barrier to greater use of this powerful technology.
“Invivofectamine® 2.0 Reagent and Ambion® In Vivo siRNA provide strong and sustained knockdown of in vivo protein expression in an easy-to-use kit,” said Charles Piazza, Head of Molecular Biology Reagents for Life Technologies. “These tools will accelerate the use of RNAi to efficiently study gene function in animal models.”
Sold as part of a 1ml starter kit or a 5ml kit, Invivofectamine® 2.0 Reagent and Ambion® In Vivo siRNA are synthetic, contain no components of viral origin, and show minimal to no toxicity after extensive initial studies.
Products are for Research Use Only and are not for use in diagnostic procedures.
About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables, and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact